Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + etoposide + liposomal doxorubicin + dexamethasone + rituximab
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
TEDD-R is a multi-agent chemoimmunotherapy regimen developed by the National Cancer Institute (NCI) for the treatment of secondary central nervous system lymphoma (sCNSL). It is a specific arm of the TEDDI-R clinical trial (NCT03964090) that omits ibrutinib, typically administered to patients whose tumors show resistance to ibrutinib lead-in therapy. The regimen consists of five agents: temozolomide (an alkylating agent), etoposide (a topoisomerase II inhibitor), Doxil (liposomal doxorubicin), dexamethasone (a corticosteroid), and rituximab (an anti-CD20 monoclonal antibody). This combination is designed to optimize CNS penetration and provide a multi-targeted approach to aggressive B-cell lymphomas with secondary CNS involvement.
- Other names
- TEDD-R regimen
02
Targets
Beyond the preview
Go deeper on temozolomide + etoposide + liposomal doxorubicin + dexamethasone + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + etoposide + liposomal doxorubicin + dexamethasone + rituximab.